Newsroom

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.

Sera announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal.

Sera announced financial results for the third quarter of 2025 ended September 30, 2025.

Sera announced it will report third quarter fiscal year 2025 financial results on Thursday November 13, 2025, after the close of the market.

Salt Lake City – October 1, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…

Salt Lake City – August 28, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…

Sera announced financial results for the second quarter of 2025 ended June 30, 2025.

Sera today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6, 2025, after the close of the market.

Sera announced that members of the Sera team will participate in upcoming investor conferences.